

LETTERS TO THE EDITOR

To the Editor—I have noticed that respiratory stimulants such as nikethamide and doxapram are used rather frequently for the management of chronic obstructive airway disease (COAD) patients in acute respiratory failure, especially by junior doctors. The drug nikethamide is a central nervous system stimulant which may cause convulsions. It reminded me of the pharmacological experiment I did as a medical student: mice given nikethamide all died quickly after jumping violently for a short time.

There is nothing about the drug in any of the major current textbooks on medicine, respiratory medicine, or pharmacology. A literature search using Medline showed that in the past five years there has been only one study on the use of nikethamide in COAD patients with acute exacerbation. The authors concluded that "all the changes demonstrated that nothing is worthwhile with the treatment of nikethamide, but a side effect from increasing work of breathing and consumption of oxygen".¹ I believe that a drug which is ineffective and hazardous should not be used clinically. Doxapram may be a better choice in selected patients who are properly monitored and managed.^{2,3} However, it should be noted that patients who are exhausted are unlikely to benefit from doxapram, and the drug may actually worsen the diaphragm dysfunction.⁴ Mechanical ventilatory support should be offered instead for patients who are potentially salvageable.

HY So, FFICANZCA, FHKAM (Anaesthesiology)
Department of Anaesthesiology and Intensive Care
Yan Chai Hospital
Tsuen Wan, Hong Kong.

References

1. Ren XH, Ding DJ, Chen EZ. Effects of oxygen and nikethamide on central drive, ventilation and blood gases of patients with obstructive lung disease in acute exacerbation of respiratory failure. *Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih* 1993;16:331-4.
2. Jeffrey AA, Warren PM, Flenley DC. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management. *Thorax* 1992;47:34-40.
3. Hirshberg AJ, Dupper RL. Use of doxapram hydrochloride injection as an alternative to intubation to treat chronic obstructive pulmonary disease patients with hypercapnia. *Ann Emerg Med* 1994;24:701-3.
4. Pourriat JL, Baud M, Lamberto C, Fosse JP, Cupa M. Effects of doxapram on hypercapnic response during weaning from mechanical ventilation in COPD patients. *Chest* 1992;101:1639-43.

To the Editor—Transfusion is the mainstay treatment for patients with thalassaemia major. It has been suggested that an annual transfusion requirement (or index) of more than 200 to 250 ml per kg mid-year body weight of packed red cells is indicative of hypersplenism.^{1,2} As a result, splenectomy is indicated, to resume an annual index of 150 to 180 ml/kg as documented in splenectomised patients.

As the blood product used in Hong Kong is different from that used in other countries (Table 1), the applicability of such an approach needed verification. We retrospectively reviewed all β -thalassaemia major patients receiving transfusion in 1993 in our unit. They were transfused at four-weekly intervals in order to maintain a mean haemoglobin level (average of pre- and post-transfusion haemoglobin levels) of 12 g/dL. The total number of units and volume of blood given, pre- and post-transfusion haemoglobin levels, and the mid-year body weight were included in the analysis. The results are shown in Table 2.

Fifty-six patients received 722 transfusions; these were divided into two groups according to whether they were splenectomised or not. The mean transfusion indices in splenectomised and non-splenectomised patients were 258 ml/kg and 315 ml/kg, respectively. Using the mean plus two standard deviations as the upper limit, three children had indices that exceeded 400 ml/kg/y. Two had progressive splenomegaly and developed thrombocytopenia while waiting for splenectomy; no complications were detected in the other patients.

In conclusion, thalassaemic patients should be evaluated for splenectomy when their annual transfusion index exceeds 1.2 units/kg or 400 ml/kg of plasma-reduced red cells. This is in line with the upper limit recommended by the Thalassaemia International Federation of 1.5 times the annual consumption in splenectomised patients.³ Numerical limits without reference to the type of blood product published elsewhere cannot be applied locally.

ACW Lee, MRCP
SY Ha, MRC Path
YL Lau, MD
Department of Paediatrics
Queen Mary Hospital
Pokfulam, Hong Kong

Table 1. Comparison of red cell products used in Hong Kong and the United Kingdom

	Hong Kong ⁴	United Kingdom ⁵
Blood product	Plasma-reduced red cells	Red cell concentrate
Average volume (ml)		
Average haematocrit	0.55	0.65

Table 2. Transfusion requirements in thalassaemia major patients

Splenuctomised	No.	Sex M:F	Age (y)	Mean Hb(g/dL)	Transfusion requirement	
					TU (units/kg)	TV (ml/kg)
Yes	9	6:3	16.2±3.6	12.2±0.5	0.77±0.08	258±30
No	47	21:26	12.5±5.0	12.2±0.5	0.95±0.12	315±42
Total	56	27:29	13.1±5.0	12.2±0.5	0.92±0.13	306±45

Figures are expressed as mean ± 1 SD

Hb = haemoglobin

TU = total units of blood transfused divided by mid-year body weight

TV = total volume of blood transfused divided by mid-year body weight

References

1. Li CK. Management of common haematological disorders. In: Chiu MC, editor. Paediatric manual. Hong Kong: Hong Kong University Press, 1991:292-9.
2. Piomelli S, Loew T. Management of thalassaemia major (Cooley's anemia). *Hematol Oncol Clin North Am* 1991;5: 557-69.
3. Cao A, Gabutti V, Masera G, Modell B, Sarchia G, Vullo C. Management protocol for the treatment of thalassaemia patients. Cyprus: Thalassaemia International Federation, 1992:17-8.
4. Liu HW. Handbook of transfusion medicine. Hong Kong: Hong Kong Red Cross Blood Transfusion Service, 1993:5.
5. McClelland DB. Handbook of transfusion medicine. London: HMSO, 1989:9.

To the Editor—I am greatly concerned after reading a report published by Apple Daily (July 20, 1995) in which they succeeded in buying isotretinoin from a number of chemists without prescriptions. In fact, the drug is not supposed to be sold by pharmacists: the drug company, Roche, only sells it to holders of a diploma in dermatology.

Isotretinoin has been found useful in a number of conditions including cystic acne, acne rosacea and gram negative folliculitis, Darier's disease, and pityriasis rubra. The precise mechanism of action is not clear. Isotretinoin exerts numerous actions including the inhibition of sebum synthesis, the lowering of *Propionibacterium acnes* concentrations and the inhibition of neutrophil chemotaxis. It also has comedolytic and anti-inflammatory properties.

There is a tendency for the indications for isotretinoin to be broadened to include those suffering from less severe acne. The reasons are as follows:

1. On average, sebum production will decline by 30% from 20 weeks to 99 weeks post treatment.¹ To some patients, this is almost a "cure" because puberty will be over by then.
2. Isotretinoin not only improves the physical appearance of teenagers, it also improves their psychological well-being.²